By enabling the elimination of the entire P-TEFb complex, this MDM2-recruiting degradation strategy expands the toolkit for targeting CDK9 and represents a promising new therapeutic paradigm for <i>TP53</i> wild-type cancers. The gene discussed is CDK9; the disease is cancer.